| Identification | Back Directory | [Name]
Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- | [CAS]
934995-88-7 | [Synonyms]
MK-0952 Sodium
MK0952 Sodium,MK 0952 Sodium
Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- | [Molecular Formula]
C28H21FN3NaO4 | [MDL Number]
MFCD20527260 | [MOL File]
934995-88-7.mol | [Molecular Weight]
505.472 |
| Hazard Information | Back Directory | [Uses]
MK-0952 sodium is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 sodium has the potential for Alzheimer’s disease study[1][2]. | [References]
[1] Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21. DOI:10.1016/j.bmcl.2010.09.087
[2] Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33. DOI:10.1016/j.bmcl.2019.06.056 |
|
|